Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL BaSyc is ...
The primary goal of the trial was to optimize radiation therapy (RT) dose among three levels (low, standard, and high), given either with placebo (P) or an investigational agent (A), for treating ...
In traditional schedule or dose–schedule finding designs, patients are assumed to receive their assigned dose–schedule combination throughout the trial even though the combination may be found to have ...
An innovative approach to a phase II clinical trial aims to test the effects of multiple targeted treatments simultaneously in participants in the UK National Lung Matrix Trial. The design makes it ...
The US Food and Drug Administration (FDA) last week finalized guidance on adaptive clinical trial designs for drugs and biologics. The 33-page guidance, which finalizes a draft version released for ...
The US Food and Drug Administration (FDA) on Friday unveiled two draft guidances focused on adaptive clinical trial designs and master protocols for cancer treatment trials. The 32-page adaptive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback